Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (288)
- COVID-19 (164)
- Safety monitoring and information (112)
- Compliance and enforcement (85)
- Legislation (77)
- Manufacturing (59)
- Vaping hub (56)
- Labelling and packaging (41)
- Import and export (35)
- Medicinal cannabis hub (27)
- Scheduling (national classification system) (27)
- Sunscreens (20)
- Weight loss products (18)
- Shortages and supply disruptions (11)
- Committees and advisory bodies (9)
- Cosmetics (6)
- Unique Device Identification (UDI) hub (5)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1273 result(s) found, displaying 1226 to 1250
-
Media releasesPharmacy software vendor links to TGA adverse event reporting web service
-
Media releasesSenator Fiona Nash, Assistant Minister for Health, has launched the Medicine Shortages Information Initiative.
-
Safety updatesMedical Devices Safety Update, Volume 2, Number 3, May 2014
-
Media releases
-
Regulatory decision noticesApproval of the Therapeutic Goods
-
Regulatory decision noticesApproval of the manner of making requests under subsection 9D(3) of the Therapeutic Goods Act 1989 to vary the entry in the Australian Register of Therapeutic Goods of registered therapeutic goods
-
Media releasesConsultation on low value turnover exemption (LVT) scheme
-
-
Media releasesThe amendments made to the Therapeutic Goods Act 1989 (the Act) by the Therapeutic Goods Amendment (2013 Measures No. 1) Act 2014 commenced on 28 February 2014.
-
Media releasesThe TGA and Medsafe have developed a common list of colouring substances allowed in medicines for oral and topical use.
-
Media releasesThe TGA reviewed studies on tartrazine, a yellow colouring used in medicines, and found it safe when properly labelled, with no strong evidence of harm like allergies or behavioural issues.
-
Media releases
-
Media releasesNew Zealand changes paediatric dosage instructions for paracetamol and ibuprofen to align with Australia.
-
Media releasesPilot web service for transmission of adverse event reports from medical software to the Therapeutic Goods Administration
-
Safety updatesMedical Devices Safety Update, Volume 2, Number 1, January 2014
-
News articlesThe TGA is advising consumers against purchasing or using black salve, red salve or cansema products.
-
Safety updatesMedicines Safety Update, Volume 4, Number 4, August 2013
-
Compliance undertakingsTHERAPEUTIC GOODS ACT 1989
Undertaking to the Secretary of the Australian Department of Health and Ageing given for the purposes of section 42YL of the Act -
Regulatory decision noticesMifepristone and misoprostol can be prescribed in Australia by registered medical practitioners.
-
Safety updatesHospital supply departments, health professionals, carers and users should check that male urinal bottles are free of sharp edges, both inside and outside the bottle. Any cracks, chips or sharp edges may injure users.
-
Safety updatesThe TGA Prescription Medicines Streamlined Submissions Process Newsletter [formerly the Prescription medicine BPR update (BPR update)] reports on progress of the streamlined submission process.
-
Safety updatesWe have received reports of haemodialysis catheters becoming dislodged at the Luer lock connection point. In some cases, the dislodgement was not detected, as the catheter and all connections were out of sight.
-
Safety updatesThe Prescription medicine BPR update (BPR update) reports on progress of the streamlined submission process. Each quarter, an update is provided on the PI/CMI project and the AusPAR project.
-
Media releasesThe Australian government will introduce a comprehensive package of reforms for Australia's Therapeutic Goods Administration (TGA) to ensure the regulation of medicines and medical devices is more effective and transparent.
-
Media releasesThe TGA intends to cancel all pain-killers containing dextropropoxyphene - Capadex, Di-Gesic, Doloxene and Paradex - from the Australian Register of Therapeutic Goods (ARTG), from 1 March 2012.